



NDA 21636/S011
NDA 21849/S006

SUPPLEMENT APPROVAL

Santarus, Inc.
Attention: Maria Bedoya-Toro, PhD, MBA
Vice President
Regulatory Affairs and Quality Assurance
3721 Valley Center Drive, Suite 400
San Diego, CA 92130

Dear Dr. Bedoya-Toro:

Please refer to your Supplemental New Drug Applications (sNDA's) dated June 20, 2011, received June 21, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zegerid (omeprazole/sodium bicarbonate) Powder for Oral Suspension and Zegerid (omeprazole/sodium bicarbonate) Capsules.

We acknowledge receipt of your amendments dated October 3, 2011 and November 29, 2011.

These supplemental new drug applications provide for labeling revisions to reflect the drug interaction between omeprazole and clopidogrel, as requested, with no additional changes.

We have completed our review of the supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text. Please update the revision date on the label to reflect the date of this approval.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, etc.), with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

If you have any questions, call Stacy Barley, Regulatory Project Manager, at (301) 796-2137.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors
Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
12/07/2011